BioCanRx Open Call for Research Proposals
Call Objectives & Research Scope
Building on this feedback, we are pleased to invite research proposals spanning various topics falling within cancer immunotherapy and biotherapeutic translation. For the purposes of this call, cancer immunotherapy is defined as all therapeutic products that modulate the immune system.
Proposals should aim to address at least one of the following objectives:
- Accelerate Cancer Immunotherapy and Biotherapeutic Product Innovations from Bench to Bedside: Develop and translate promising innovations from proof of concept through to clinical application (i.e. Phase I/II clinical trials).
- Address the Clinical, Social, Economic, Regulatory and Policy Elements of these Innovations: Identify and address the barriers to the adoption and integration of these therapies into clinical practice and Canada’s healthcare system.
- Support Technology Innovation through Core Facility Activities: Canadian academic infrastructure and technologies that support the advancement and production of cancer immunotherapies and biotherapeutics.
This call for research proposals includes BioCanRx’s five established funding programs:
- Catalyst Program: Short-term, early-stage proof-of-concept studies that will advance cancer biotherapeutics development, assessment or clinical translation. Projects may be oriented toward companion technologies or methodologies, or combination therapeutic strategies.
- Enabling Studies Program: Prepare and position biotherapeutic products and platforms for clinical testing in patients, including GMP manufacturing and process development. Enabling Study projects should result in either CTA submission packages or Quality (Chemistry and Manufacturing) packages.
- Clinical Trials Program: Phase I/II clinical trials of novel cancer biotherapies that have been substantially developed in Canada.
- Clinical, Social and Economic Impact (CSEI) Program: Identify and address the barriers to the adoption and integration of these therapies into clinical practice and Canada’s healthcare system.
- Core Facilities Program: Manufacturing or research technologies and/or services that support the advancement and production of cancer immunotherapies and biotherapeutics.
